SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-000737
Filing Date
2022-01-10
Accepted
2022-01-10 06:01:34
Documents
13
Period of Report
2022-01-07
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36380
  Complete submission text file 0001493152-22-000737.txt   259586

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20220107.xsd EX-101.SCH 3887
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20220107_def.xml EX-101.DEF 27463
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20220107_lab.xml EX-101.LAB 37864
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20220107_pre.xml EX-101.PRE 26082
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5891
Mailing Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140
Business Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140 (305) 204-3338
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 22519517
SIC: 2836 Biological Products, (No Diagnostic Substances)